Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.
Type:
Application
Filed:
June 4, 2018
Publication date:
January 3, 2019
Applicant:
Genentech, Inc.
Inventors:
Natarajan VIJAYASANKARAN, Steven J. MEIER, Sharat VARMA, Yi YANG
Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
December 25, 2018
Assignee:
Genentech, Inc.
Inventors:
Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang
Abstract: Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.
Abstract: The present invention relates to anti-Ebola virus envelope glycoprotein antibodies. The invention further relates to diagnostic methods which utilize the anti-Ebola virus glycoprotein antibodies and to pharmaceutical compositions which employ these antibodies therapeutically and prophylactically.
Abstract: Monoclonal and polyclonal antibodies that bind hamster phospholipase B-like 2 are provided. Also provided are methods for detecting and quantifying hamster phospholipase B-like 2, for example, in recombinant polypeptide preparations, as well as kits for carrying out such methods. Methods of screening or selecting host cell lines or recombinant polypeptide-expressing cell lines that express low levels of hamster phospholipase B-like 2 are also provided.
Type:
Application
Filed:
March 7, 2018
Publication date:
December 20, 2018
Applicant:
Genentech, Inc.
Inventors:
Feny Gunawan, Yi-Chun Hsiao, Denise C. Krawitz, Margaret S. Lin, Martin Vanderlaan, Rajesh Vij, Inn H. Yuk, Judith Zhu-Shimoni
Abstract: Monoclonal and polyclonal antibodies that bind hamster phospholipase B-like 2 are provided. Also provided are methods for detecting and quantifying hamster phospholipase B-like 2, for example, in recombinant polypeptide preparations, as well as kits for carrying out such methods. Methods of screening or selecting host cell lines or recombinant polypeptide-expressing cell lines that express low levels of hamster phospholipase B-like 2 are also provided.
Type:
Application
Filed:
March 7, 2018
Publication date:
December 20, 2018
Applicant:
Genentech, Inc.
Inventors:
Feny Gunawan, Yi-Chun Hsiao, Denise C. Krawitz, Margaret S. Lin, Martin Vanderlaan, Rajesh Vij, Inn H. Yuk, Judith Zhu-Shimoni
Abstract: The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
March 3, 2017
Date of Patent:
December 18, 2018
Assignees:
GENENTECH, INC, CONSTELLATION PHARMACEUTICALS, INC.
Inventors:
Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, Anthony F. Romero, Alexander M. Taylor
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Type:
Grant
Filed:
August 23, 2017
Date of Patent:
December 18, 2018
Assignees:
Array BioPharma Inc., Genentech, Inc.
Inventors:
James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
Abstract: The present invention relates to methods of treating liver cancer using a Notch signaling inhibitor. Compositions and methods for the treatment of liver cancers are also provided.
Type:
Application
Filed:
April 27, 2018
Publication date:
December 13, 2018
Applicant:
Genentech, Inc.
Inventors:
Dorothy French, Erik Huntzicker, Christian W. Siebel
Abstract: Methods of detecting and quantifying IL-13 are provided. Also provided are methods of diagnosing, selecting and identifying patients with Th2-associated diseases (Type 2-associated diseases) for treatment with certain therapeutic agents that are Th2 pathway inhibitors (Type 2 pathway inhibitors).
Type:
Application
Filed:
September 11, 2017
Publication date:
December 13, 2018
Applicants:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Alyssa Morimoto, Kun Peng, Heleen Scheerens, Fang Cai, Hans Hornauer
Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to an anthracycline drug moiety via a disulfide linker, anthracycline disulfide intermediates, and methods of using the antibody-drug conjugates.
Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
Type:
Grant
Filed:
May 10, 2017
Date of Patent:
December 11, 2018
Assignees:
Genentech, Inc., Constellation Pharmaceuticals Inc.
Inventors:
Brian K. Albrecht, Steven F. Bellon, Daniel J. Burdick, Alexandre Cote, Terry Crawford, Les A. Dakin, Vickie Hsiao-Wei Tsui, Michael Charles Hewitt, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, Anthony F. Romero, Yong Tang, Alexander M. Taylor, Shumei Wang
Abstract: The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same.
Type:
Application
Filed:
December 18, 2017
Publication date:
December 6, 2018
Applicant:
Genentech, Inc.
Inventors:
Mark DENNIS, William MALLET, Paul POLAKIS